Quick Dispatch:
Your surpass trial tirzepatide Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme | Diabetes Therapy orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass trial tirzepatide Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme | Diabetes Therapy ships.
Need Help?
Questions about surpass trial tirzepatide Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme | Diabetes Therapy, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass trial tirzepatide Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme | Diabetes Therapy in your area.
SURMOUNT-1 Trial
22.69
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
28.86
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
21.95
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials
25.23
Tirzepatide (Mounjaro) received a priority review from @US_FDA for #T2D reflecting the unprecedented reductions in A1c and #weightloss across the SURPASS P3 clinical trial program
22.72
Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program
28.10
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme - Bergman - 2025 - Diabetes, Obesity and Metabolism
28.11
